Difficulties in diagnosing GERD in the absence of esophageal manifestations. Clinical observation

2021 ◽  
pp. 25-32
Author(s):  
Larisa Vladimirovna Bychkova ◽  
Anastasia Sergeevna Zhuravleva ◽  
Mikhail Grigorevich Rodoman ◽  
Olga Yurievna Markina ◽  
Malika Mansurovna Irkabaeva

The tendency towards an increase in the incidence of GERD served as the basis for the announcement of the slogan "XX century is the century of peptic ulcer disease, XXI century is the century of GERD" at the 6th European Gastroenterological Week (Birmingham, 1997). The article presents a clinical observation of a patient suffering from gastroesophageal reflux disease. The interest and peculiarity of the case lies in the difficulty of making the above-mentioned diagnosis, when the disease is manifested by extraesophageal symptoms: hoarseness, nasal congestion, glossitis, coughing, and cardiac pathology. In this case, the only manifestation of gastroesophageal reflux disease was persistent dry cough.

Author(s):  
Rawan Ageeli ◽  
Abdullah Binobaid ◽  
Abdullah Aljadaan ◽  
Mohammed Alhagbani ◽  
Yasser Alotaibi ◽  
...  

Background: Proton pump inhibitors (PPIs) are one of the most commonly used classes of drugs. Though, the quantum clinical benefit of newer and more expensive PPIs over the older generation PPIs residues undefined. The present meta-analysis ought to assess the safety and clinical profiles of esomeprazole versus omeprazole at pharmacologically equivalent doses in healing gastroesophageal reflux disease (GERD), peptic ulcer disease and eradicating Helicobacter pylori infection.Methods: PubMed and the Cochrane Library were searched for randomized controlled trials comparing esomeprazole with omeprazole at all doses up to July 2017. Meta-analysis was conducted using a random effects model, and heterogeneity in the estimated effects was investigated using meta-regression.Results: Eleven trials were included and none of which compared esomeprazole with omeprazole in peptic ulcer disease. In gastroesophageal reflux disease, esomeprazole 40 mg (relative risk (RR) = 1.11; 95% confidence interval (CI) 1.14 to 1.23) and 20 mg (RR=1.08; 95% CI 1.02 to 1.12) significantly improved esophagitis healing when compared with omeprazole 20 mg at week 8. In H. pylori eradication, there was no difference in the treatment effects between esomeprazole 20 mg and omeprazole 20 mg (RR = 1.05;95% CI 1.01 to 1.11).Conclusions: Esomeprazole established better esophagitis healing rate in patients with GERD than omeprazole at week 8. Though, this clinical advantage reduced when both drugs were given at the same doses at week 4. Superiority of esomeprazole was not perceived in the H. pylori eradication rates.


2008 ◽  
Vol 1 ◽  
pp. CGast.S523
Author(s):  
Alan B.R. Thomson

The entire field of gastroenterology is primed to take an enormous step forward, with scientific and endoscopic advances which will be tothis decade what the treatments of peptic ulcer disease and viral hepatitis conditions were for the 80's and 90's. So also in the area of esophagology there are numerous emerging techniques and scientific advances in our understanding of the motor and sensory function of the esophagus. These contribute to our better understanding of common conditions such as gastroesophageal reflux disease (GERD) including erosive esophagitis (EE), normal endoscopy reflux disease (NERD), Barrett's epithelium (BE), and esophageal adenocarcinoma (ECA), as well as the less common esophageal motility disorders, oro-pharyngeal dysphagia and eosinophilic esophagitis.


Sign in / Sign up

Export Citation Format

Share Document